Analysts Expect Ritter Pharmaceuticals Inc (NASDAQ:RTTR) to Announce -$0.45 EPS
Analysts predict that Ritter Pharmaceuticals Inc (NASDAQ:RTTR) will report earnings of ($0.45) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Ritter Pharmaceuticals’ earnings. Ritter Pharmaceuticals reported earnings of ($0.71) per share during the same quarter last year, which suggests a positive year over year growth rate of 36.6%. The firm is scheduled to report its next earnings report on Tuesday, August 13th.
On average, analysts expect that Ritter Pharmaceuticals will report full year earnings of ($1.30) per share for the current fiscal year. For the next financial year, analysts forecast that the business will post earnings of ($0.55) per share. Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Ritter Pharmaceuticals.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.14.
A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Virtu Financial LLC acquired a new stake in shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 52,426 shares of the biotechnology company’s stock, valued at approximately $46,000. Virtu Financial LLC owned 0.91% of Ritter Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 6.09% of the company’s stock.
Shares of Ritter Pharmaceuticals stock traded down $0.02 during trading hours on Friday, hitting $0.89. The company’s stock had a trading volume of 12,918 shares, compared to its average volume of 413,498. The stock has a 50 day moving average price of $1.01. Ritter Pharmaceuticals has a 12-month low of $0.47 and a 12-month high of $2.56. The firm has a market cap of $9.16 million, a P/E ratio of -0.24 and a beta of 1.27.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Read More: Gap Up Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.